The FDA has approved changes to the labeling of Merck's finasteride (Proscar) that reflect data from the National Institutes of Health's MTOPS study, which showed that finasteride in combination with doxazosin mesylate (Cardura) reduced the risk of progression of symptoms of benign prostatic hyperplasia (BPH) by 64% when compared with placebo and either drug alone. Doxazosin is a product of Pfizer.

Finasteride, administered in combination with doxazosin, is now indicated to reduce the risk of symptoms of BPH from progressing over time (a confirmed rise of 4 or more points in the American Urological Association symptom score).

Consult the product labels of finasteride and doxazosin for full prescribing information.